Basilea earns $1.25M from Pfizer as Cresemba sales in APAC and China exceed milestone.

Basilea Pharmaceutica announced that Pfizer's sales of the antifungal drug Cresemba (isavuconazole) in the Asia Pacific region and China exceeded a milestone threshold, resulting in a $1.25 million payment to Basilea. This is the fourth milestone payment this year, highlighting Cresemba's growing demand. Approved in over 70 countries, including the U.S. and EU, Cresemba is effective against invasive mold infections and has seen a 20% annual sales increase.